
Frederick G Hayden

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1776320/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel coronavirus outbreak of global health concern. Lancet, The, 2020, 395, 470-473.	13.7	5,656
2	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2020, 395, 1569-1578.	13.7	2,875
3	Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 2020, 46, 854-887.	8.2	1,536
4	Avian Influenza A (H5N1) Infection in Humans. New England Journal of Medicine, 2005, 353, 1374-1385.	27.0	1,235
5	Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus Infection. New England Journal of Medicine, 2010, 362, 1708-1719.	27.0	1,003
6	Corticosteroid Therapy for Critically III Patients with Middle East Respiratory Syndrome. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 757-767.	5.6	911
7	Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza. JAMA - Journal of the American Medical Association, 2000, 283, 1016.	7.4	909
8	Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine, 2020, 48, e440-e469.	0.9	816
9	Update on Avian Influenza A (H5N1) Virus Infection in Humans. New England Journal of Medicine, 2008, 358, 261-273.	27.0	814
10	Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections. New England Journal of Medicine, 1997, 337, 874-880.	27.0	746
11	Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet, The, 2004, 364, 759-765.	13.7	735
12	Oral oseltamivir treatment of influenza in children. Pediatric Infectious Disease Journal, 2001, 20, 127-133.	2.0	684
13	Influenza virus neuraminidase inhibitors. Lancet, The, 2000, 355, 827-835.	13.7	642
14	Kinetics of Influenza A Virus Infection in Humans. Journal of Virology, 2006, 80, 7590-7599.	3.4	630
15	Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 2018, 379, 913-923.	27.0	629
16	Seasonal Influenza in Adults and Children—Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2009, 48, 1003-1032.	5.8	604
17	Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. JAMA - Journal of the American Medical Association, 1999, 282, 1240.	7.4	500
18	Use of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza. New England Journal of Medicine, 1999, 341, 1336-1343.	27.0	477

#	Article	IF	CITATIONS
19	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical Infectious Diseases, 2019, 68, e1-e47.	5.8	449
20	Impact of Oseltamivir Treatment on Influenza-Related Lower Respiratory Tract Complications and Hospitalizations. Archives of Internal Medicine, 2003, 163, 1667.	3.8	443
21	Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families. New England Journal of Medicine, 1989, 321, 1696-1702.	27.0	415
22	Inhaled Zanamivir for the Prevention of Influenza in Families. New England Journal of Medicine, 2000, 343, 1282-1289.	27.0	351
23	Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrobial Agents and Chemotherapy, 2006, 50, 2395-2402.	3.2	333
24	Symptom pathogenesis during acute influenza: Interleukinâ€6 and Other cytokine responses. Journal of Medical Virology, 2001, 64, 262-268.	5.0	320
25	Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. Journal of Infection, 2013, 67, 606-616.	3.3	314
26	Management of Influenza in Households: A Prospective, Randomized Comparison of Oseltamivir Treatment With or Without Postexposure Prophylaxis. Journal of Infectious Diseases, 2004, 189, 440-449.	4.0	301
27	Surviving Sepsis Campaign Guidelines on the Management of Adults With Coronavirus Disease 2019 (COVID-19) in the ICU: First Update. Critical Care Medicine, 2021, 49, e219-e234.	0.9	289
28	Efficacy and Safety of Oral Pleconaril for Treatment of Colds Due to Picornaviruses in Adults: Results of 2 Double-Blind, Randomized, Placebo-Controlled Trials. Clinical Infectious Diseases, 2003, 36, 1523-1532.	5.8	270
29	Detection of Rhinovirus, Respiratory Syncytial Virus, and Coronavirus Infections in Acute Otitis Media by Reverse Transcriptase Polymerase Chain Reaction. Pediatrics, 1998, 102, 291-295.	2.1	267
30	Recovery of Drugâ€Resistant Influenza Virus from Immunocompromised Patients: A Case Series. Journal of Infectious Diseases, 2006, 193, 760-764.	4.0	253
31	Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clinical Infectious Diseases, 2019, 68, 895-902.	5.8	251
32	Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?. Clinical Infectious Diseases, 2009, 48, S3-S13.	5.8	239
33	Rhinovirus and the lower respiratory tract. Reviews in Medical Virology, 2004, 14, 17-31.	8.3	224
34	Safety and Efficacy of the Neuraminidase Inhibitor GG167 in Experimental Human Influenza. JAMA - Journal of the American Medical Association, 1996, 275, 295.	7.4	222
35	Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-1²1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 2018, 19, 81.	1.6	221
36	Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection. Antimicrobial Agents and Chemotherapy, 2006, 50, 1470-1479.	3.2	211

#	Article	IF	CITATIONS
37	Prevention of Natural Colds by Contact Prophylaxis with Intranasal Alpha ₂ -Interferon. New England Journal of Medicine, 1986, 314, 71-75.	27.0	206
38	Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2003, 47, 3907-3916.	3.2	205
39	Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors. Antimicrobial Agents and Chemotherapy, 2005, 49, 4515-4520.	3.2	197
40	Comparison of the Activities of Zanamivir, Oseltamivir, and RWJ-270201 against Clinical Isolates of Influenza Virus and Neuraminidase Inhibitor-Resistant Variants. Antimicrobial Agents and Chemotherapy, 2001, 45, 3403-3408.	3.2	192
41	Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infectious Diseases, The, 2012, 12, 240-248.	9.1	186
42	Rhinovirus and Coronavirus Infection–Associated Hospitalizations among Older Adults. Journal of Infectious Diseases, 2002, 185, 1338-1341.	4.0	184
43	Efficacy of Tremacamra, a Soluble Intercellular Adhesion Molecule 1, for Experimental Rhinovirus Infection. JAMA - Journal of the American Medical Association, 1999, 281, 1797.	7.4	180
44	Influenza virus polymerase inhibitors in clinical development. Current Opinion in Infectious Diseases, 2019, 32, 176-186.	3.1	180
45	Prolonged Shedding of Amantadine-Resistant Influenza A Viruses by Immunodeficient Patients: Detection by Polymerase Chain Reaction-Restriction Analysis. Journal of Infectious Diseases, 1995, 172, 1352-1355.	4.0	172
46	Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Medicine, 2020, 46, 315-328.	8.2	172
47	Antiviral Resistance in Influenza Viruses — Implications for Management and Pandemic Response. New England Journal of Medicine, 2006, 354, 785-788.	27.0	169
48	WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infectious Diseases, The, 2007, 7, 21-31.	9.1	165
49	Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus, 2015, 4, 709.	1.2	163
50	Emerging Influenza Antiviral Resistance Threats. Journal of Infectious Diseases, 2011, 203, 6-10.	4.0	159
51	Antiviral combinations for severe influenza. Lancet Infectious Diseases, The, 2014, 14, 1259-1270.	9.1	159
52	Localization of Human Rhinovirus Replication in the Upper Respiratory Tract by In Situ Hybridization. Journal of Infectious Diseases, 1995, 171, 1329-1333.	4.0	154
53	Development of Common Cold Symptoms Following Experimental Rhinovirus Infection is Related to Prior Stressful Life Events. Behavioral Medicine, 1992, 18, 115-120.	1.9	144
54	Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Research, 2001, 49, 147-156.	4.1	142

#	Article	IF	CITATIONS
55	Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Research, 2002, 53, 47-61.	4.1	139
56	Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. Critical Care Medicine, 2017, 45, 1683-1695.	0.9	139
57	Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infectious Diseases, The, 2020, 20, 1204-1214.	9.1	134
58	Antiviral Effects on Influenza Viral Transmission and Pathogenicity: Observations from Household-based Trials. American Journal of Epidemiology, 2006, 165, 212-221.	3.4	130
59	Safety and Efficacy of Intravenous Zanamivir in Preventing Experimental Human Influenza A Virus Infection. Antimicrobial Agents and Chemotherapy, 1999, 43, 1616-1620.	3.2	129
60	Rhinovirus Infections in Hematopoietic Stem Cell Transplant Recipients with Pneumonia. Clinical Infectious Diseases, 2003, 36, 1139-1143.	5.8	129
61	Antivirals targeting the polymerase complex of influenza viruses. Antiviral Research, 2019, 169, 104545.	4.1	122
62	In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication. Antimicrobial Agents and Chemotherapy, 2002, 46, 1014-1021.	3.2	110
63	Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-1²1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials, 2020, 21, 8.	1.6	108
64	Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infectious Diseases, The, 2015, 15, 840-851.	9.1	107
65	Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza. Journal of Infectious Diseases, 2020, 221, 346-355.	4.0	104
66	Macrolides in critically ill patients with Middle East Respiratory Syndrome. International Journal of Infectious Diseases, 2019, 81, 184-190.	3.3	103
67	Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically III Patients With Influenza Virus Infection. Journal of Infectious Diseases, 2020, 221, 1688-1698.	4.0	103
68	Rimantadine Hydrochloride and Amantadine Hydrochloride Use in Influenza A Virus Infections. Infectious Disease Clinics of North America, 1987, 1, 459-478.	5.1	103
69	Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza. Antiviral Therapy, 2003, 8, 183-190.	1.0	103
70	Polymerase chain reaction–based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion. Journal of Pediatrics, 1998, 133, 390-394.	1.8	101
71	Antiviral Management of Seasonal and Pandemic Influenza. Journal of Infectious Diseases, 2006, 194, S119-S126.	4.0	100
72	Baloxavir Marboxil in Japanese Pediatric Patients With Influenza: Safety and Clinical and Virologic Outcomes. Clinical Infectious Diseases, 2020, 71, 971-981.	5.8	99

#	Article	IF	CITATIONS
73	Efficacy and Tolerability of the Oral Neuraminidase Inhibitor Peramivir in Experimental Human Influenza: Randomized, Controlled Trials for Prophylaxis and Treatment. Antiviral Therapy, 2005, 10, 901-910.	1.0	99
74	Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults. Archives of Internal Medicine, 2000, 160, 3234.	3.8	96
75	Perspectives on antiviral use during pandemic influenza. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 1877-1884.	4.0	95
76	Relationship of Pleconaril Susceptibility and Clinical Outcomes in Treatment of Common Colds Caused by Rhinoviruses. Antimicrobial Agents and Chemotherapy, 2005, 49, 4492-4499.	3.2	94
77	Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts. New England Journal of Medicine, 2020, 383, 309-320.	27.0	93
78	Emerging novel and antimicrobial-resistant respiratory tract infections: new drug development and therapeutic options. Lancet Infectious Diseases, The, 2014, 14, 1136-1149.	9.1	91
79	Noninvasive ventilation in critically ill patients with the Middle East respiratory syndrome. Influenza and Other Respiratory Viruses, 2019, 13, 382-390.	3.4	91
80	Antivirals for influenza: Historical perspectives and lessons learned. Antiviral Research, 2006, 71, 372-378.	4.1	83
81	Oral Oseltamivir in Human Experimental Influenza B Infection. Antiviral Therapy, 2000, 5, 205-213.	1.0	81
82	Increased Interleukin-6 Levels in Nasal Lavage Samples following Experimental Influenza A Virus Infection. Vaccine Journal, 1998, 5, 604-608.	2.6	78
83	Cardiac Findings during Uncomplicated Acute Influenza in Ambulatory Adults. Clinical Infectious Diseases, 2005, 40, 415-422.	5.8	72
84	Modification of experimental rhinovirus colds by receptor blockade. Antiviral Research, 1988, 9, 233-247.	4.1	71
85	Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. Antiviral Therapy, 2009, 14, 751-762.	1.0	71
86	Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages. Journal of Clinical Virology, 2001, 21, 9-16.	3.1	68
87	Transmission of Avian Influenza Viruses to and between Humans. Journal of Infectious Diseases, 2005, 192, 1311-1314.	4.0	68
88	Clinical and epidemiological importance of influenza a viruses resistant to amantadine and rimantadine. Reviews in Medical Virology, 1992, 2, 89-96.	8.3	67
89	Trends in Clinical Practice Rhinoviruses: Important respiratory pathogens. Annals of Medicine, 1998, 30, 529-537.	3.8	66
90	End Points for Testing Influenza Antiviral Treatments for Patients at High Risk of Severe and Lifeâ€Threatening Disease. Journal of Infectious Diseases, 2010, 201, 1654-1662.	4.0	65

#	Article	IF	CITATIONS
91	Newer influenza antivirals, biotherapeutics and combinations. Influenza and Other Respiratory Viruses, 2013, 7, 63-75.	3.4	60
92	Oral Pleconaril Treatment of Picornavirus-Associated Viral Respiratory Illness in Adults: Efficacy and Tolerability in Phase II Clinical Trials. Antiviral Therapy, 2002, 7, 53-65.	1.0	60
93	Combination Antiviral Therapy for Influenza: Predictions From Modeling of Human Infections. Journal of Infectious Diseases, 2012, 205, 1642-1645.	4.0	59
94	Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials, 2020, 21, 422.	1.6	59
95	Respiratory viral threats. Current Opinion in Infectious Diseases, 2006, 19, 169-178.	3.1	58
96	John F. Enders Lecture 2006: Antivirals for Influenza. Journal of Infectious Diseases, 2007, 196, 181-190.	4.0	58
97	Neuraminidase Inhibitor Susceptibility Network Position Statement: Antiviral Resistance in Influenza A/H5N1 Viruses. Antiviral Therapy, 2005, 10, 873-877.	1.0	55
98	Comparative Activities of Oseltamivir and Aâ€322278 in Immunocompetent and Immunocompromised Murine Models of Influenza Virus Infection. Journal of Infectious Diseases, 2006, 193, 765-772.	4.0	54
99	Effect of Rimantadine Treatment on Clinical Manifestations and Otologic Complications in Adults Experimentally Infected with Influenza A (H1N1) Virus. Journal of Infectious Diseases, 1998, 177, 1260-1265.	4.0	49
100	Pandemic Influenza. Pediatric Infectious Disease Journal, 2004, 23, S262-S269.	2.0	47
101	Pharmacophore Modeling, Docking, and Principal Component Analysis Based Clustering:Â Combined Computer-Assisted Approaches To Identify New Inhibitors of the Human Rhinovirus Coat Protein§. Journal of Medicinal Chemistry, 2005, 48, 6250-6260.	6.4	44
102	Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative. Future Virology, 2013, 8, 953-968.	1.8	44
103	Antivirals for Pandemic Influenza. Journal of Infectious Diseases, 1997, 176, S56-S61.	4.0	43
104	Current research on respiratory viral infections: Fourth International Symposium. Antiviral Research, 2002, 55, 227-278.	4.1	43
105	A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site. Journal of General Virology, 2002, 83, 2683-2692.	2.9	40
106	Advances in antivirals for nonâ€influenza respiratory virus infections. Influenza and Other Respiratory Viruses, 2013, 7, 36-43.	3.4	39
107	Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Frontiers of Medicine, 2020, 14, 601-612.	3.4	38
108	Immune response of adults to sequential influenza vaccination. Journal of Medical Virology, 1984, 14, 169-175.	5.0	36

#	Article	IF	CITATIONS
109	Therapeutic options for the management of influenza. Current Opinion in Pharmacology, 2001, 1, 482-490.	3.5	36
110	Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine, 2020, 62, 103125.	6.1	36
111	Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antiviral Therapy, 2003, 8, 183-90.	1.0	36
112	Combinations of antiviral agents for treatment of influenza virus infections. Journal of Antimicrobial Chemotherapy, 1986, 18, 177-183.	3.0	33
113	Current research on respiratory viral infections: Third International Symposium. Antiviral Research, 2001, 50, 157-196.	4.1	31
114	Towards improving clinical management of Middle East respiratory syndrome coronavirus infection. Lancet Infectious Diseases, The, 2014, 14, 544-546.	9.1	30
115	Experimental human influenza: observations from studies of influenza antivirals. Antiviral Therapy, 2012, 17, 133-141.	1.0	29
116	LB16. Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study). Open Forum Infectious Diseases, 2018, 5, S764-S765.	0.9	27
117	Comparative therapeutic effect of aerosolized and oral rimantadine HC1 in experimental human influenza A virus infection. Antiviral Research, 1982, 2, 147-153.	4.1	26
118	Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention. Vaccine, 2000, 19, S66-S70.	3.8	25
119	Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment. Clinical Infectious Diseases, 2022, 74, 532-540.	5.8	25
120	Influenza Therapeutics in Clinical Practice—Challenges and Recent Advances. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038463.	6.2	24
121	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Research, 2021, 194, 105158.	4.1	24
122	Experimental Therapies for Ebola Virus Disease: What Have We Learned?. Journal of Infectious Diseases, 2017, 215, jiw496.	4.0	23
123	Oral pleconaril treatment of picornavirus-associated viral respiratory illness in adults: efficacy and tolerability in phase II clinical trials. Antiviral Therapy, 2002, 7, 53-65.	1.0	23
124	Accumulation of Defective Neuraminidase (NA) Genes by Influenza A Viruses in the Presence of NA Inhibitors as a Marker of Reduced Dependence on NA. Journal of Infectious Diseases, 2002, 185, 591-598.	4.0	22
125	Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antiviral Therapy, 2005, 10, 873-7.	1.0	22
126	Post-Exposure Influenza Prophylaxis with Oseltamivir. Pharmacoeconomics, 2006, 24, 373-386.	3.3	21

#	Article	IF	CITATIONS
127	Respiratory Syncytial Virus Antivirals: Problems and Progress. Journal of Infectious Diseases, 2020, 222, 1417-1421.	4.0	19
128	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	4.1	19
129	Antiâ€infective immunoadhesins from plants. Plant Biotechnology Journal, 2015, 13, 1078-1093.	8.3	18
130	The Southeast Asian Influenza Clinical Research Network: Development and challenges for a new multilateral research endeavor. Antiviral Research, 2008, 78, 64-68.	4.1	17
131	Overview of the 3rd isirvâ€Antiviral Group Conference – advances in clinical management. Influenza and Other Respiratory Viruses, 2015, 9, 20-31.	3.4	17
132	Effects of dietary supplementation with conjugated linoleic acid on experimental human rhinovirus infection and illness. Antiviral Therapy, 2009, 14, 33-43.	1.0	17
133	Editorial Response: Rhinovirus Pneumonia: A Clinical Entity?. Clinical Infectious Diseases, 1999, 29, 533-535.	5.8	16
134	Drug resistance and influenza pandemics. Lancet, The, 2002, 359, 1862-1863.	13.7	16
135	Antiviral monotherapy for hospitalised patients with COVID-19 is not enough. Lancet, The, 2020, 396, 1310-1311.	13.7	16
136	Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. Journal of Infectious Diseases, 2022, 226, 1790-1799.	4.0	16
137	Patient-oriented pandemic influenza research. Lancet, The, 2009, 373, 2085-2086.	13.7	13
138	Antiviral Agents Against Respiratory Viruses. , 2017, , 1318-1326.e2.		11
139	Therapy of H7N9 pneumonia: current perspectives. Expert Review of Anti-Infective Therapy, 2013, 11, 1123-1126.	4.4	9
140	Influenza virus neuraminidase inhibitors: clinical aspects. International Congress Series, 2001, 1219, 797-806.	0.2	8
141	Antiviral Drugs (Other than Antiretrovirals). , 2010, , 565-610.		8
142	Combined Intranasal Ipratropium Bromide and Oxymetazoline in Experimental Rhinovirus Infection. American Journal of Rhinology & Allergy, 1998, 12, 125-130.	2.2	7
143	Editorial Commentary: Host and Viral Factors in Emergent Influenza Virus Infections. Clinical Infectious Diseases, 2014, 58, 1104-1106.	5.8	7
144	Baloxavir Treatment in Adolescents With Acute Influenza: Subgroup Analysis From the CAPSTONE-1 Trial. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 477-484.	1.3	6

#	Article	IF	CITATIONS
145	Influenza Virus. , 2016, , 1009-1058.		5
146	Infectious Diseases Society of America and Gain-of-Function Experiments With Pathogens Having Pandemic Potential. Journal of Infectious Diseases, 2016, 213, 1359-1361.	4.0	5
147	VII International Symposium on Respiratory Viral Infections. Antiviral Therapy, 2007, 12, 671-693.	1.0	5
148	Rhinovirus Genetics and Virulence. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 818-820.	5.6	4
149	Trends in Clinical Practice Rhinoviruses: Important respiratory pathogens. Annals of Medicine, 1998, 30, 529-537.	3.8	4
150	Antiviral Resistance in Influenza Viruses: Clinical and Epidemiological Aspects. , 2009, , 1011-1033.		3
151	The search for therapeutic options for Middle East Respiratory Syndrome (MERS). Journal of Infection and Public Health, 2016, 9, 213-215.	4.1	2
152	1645. Exploring Clinical and Antiviral Efficacy of Baloxavir Marboxil in a Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Study of Otherwise Healthy Adults/Adolescents in Seasonal Influenza: Impact on Regional Participants, Treatment Time and Influenza Type B Virus Infection (CAPSTONE-1 Study). Open Forum Infectious Diseases, 2018, 5, S48-S48.	0.9	2
153	Zoonotic Paramyxoviruses. , 0, , 949-966.		2
154	Neuraminidase inhibitors: assessment of limitations to greater therapeutic use. International Congress Series, 2004, 1263, 29-37.	0.2	1
155	Antivirals for Influenza: Novel Agents and Approaches. , 2008, , 179-192.		1
156	Colorado Tick Fever and Other Arthropod Borne Reoviridae. , 2016, , 841-852.		1
157	Respiratory Syncytial Virus, Human Metapneumovirus, and Parainfluenza Viruses. , 2016, , 873-902.		1
158	Serotherapy for patients with severe influenza. Lancet Respiratory Medicine, the, 2017, 5, 462-464.	10.7	1
159	Filoviruses. , 0, , 981-1007.		1
160	Drug resistance and influenza pandemics. Lancet, The, 2002, 360, 1704.	13.7	0
161	Rotaviruses. , 2016, , 853-872.		0
162	Comment to: Baloxavir efficacy in North American Adults. European Journal of Internal Medicine, 2020, 72, 99-101.	2.2	0

#	Article	IF	CITATIONS
163	Spotlight on Respiratory Viruses: Introduction. Antiviral Therapy, 2007, 12, 579-580.	1.0	Ο